Cabozantinib Plus Atezolizumab Delays Progression in mCRPC
SAN FRANCISCO — In patients with metastatic castration-resistant prostate cancer (mCRPC) whose disease progressed on a novel hormonal therapy, the combination of cabozantinib (Cabometyx) plus atezolizumab (Tecentriq) improved radiographic progression-free survival (rPFS) versus a switch to a second hormonal agent, a phase III trial showed. The so-called CONTACT-02 study included patients with extrapelvic nodal or […]
Radionuclide Therapy Tops AR-Pathway Inhibitor Switch for mCRPC
MADRID — Radiographic progression-free survival (rPFS) in metastatic castration-resistant prostate cancer (mCRPC) doubled when patients received a radionuclide ligand targeting prostate-specific membrane antigen (PSMA) instead of switching to another androgen receptor pathway inhibitor (ARPI), a randomized trial showed. In patients with prior progression on an ARPI, median rPFS increased from 5.9 months with another ARPI […]